Loading...
Uploaded by ndtv on Jan 19, 2008
Ranbaxy's profits beat expectations, Biocon's shot in the arm came from a plan to list its subsidiary Syngene. The revenues of Ranbaxy grew by 5.7 per cent to about Rs 1,800 crore for the fourth quarter ended December 31.
News & Politics
Standard YouTube License
Load more suggestions
All Comments